Search

Search Results

• 

  SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials

  Tariq Jamal Siddiqi, Javed Butler, Andrew J.S. Coats, Subodh Verma, Tim Friede, Gerasimos Filippatos, Stefan D. Anker

  2023-11-23

  https://doi.org/10.4081/cardio.2023.2

  1079

  pdf: 242

  Supplementary Material: 39

  HTML: 118

• Optimized heart failure therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial

  Markus S. Anker, Sven Bercker, Ulrich Laufs, Michael Böhm, Bela Merkely, Monika Diek, Tim Heise, Martin Hellmich, Marius Placzek, Tim Friede, Stefan D. Anker, Lorenz Lehmann, Ulf Landmesser, Dominik P. Modest, Muhammad Shahzeb Khan, Amir A. Mahabadi, Matthias Totzeck, Mitra Tewes, Muhammad Sameer Arshad, Raluca Mincu, Javed Butler, Ulrich Keller, Johann Ahn, Lars Bullinger, Tienush Rassaf

  2025-08-20

  https://doi.org/10.4081/cardio.2025.78

  344

  PDF: 335

  Appendix: 206

  HTML: 52
• 

  The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis

  Muhammad Shariq Usman, Arsalan Hamid, Shurjeel Uddin Qazi, Mikhail N. Kosiborod, Deepak L. Bhatt, Muhammad Shahzeb Khan, Muthiah Vaduganathan, Javed Butler

  2024-06-28

  https://doi.org/10.4081/cardio.2024.35

  2441

  PDF: 654

  Conflict of interest: 320

  SUPPLEMENTARY MATERIAL: 256

  HTML: 61
• 

  Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial

  Stephan von Haehling, Wolfram Doehner, Ruben Evertz, Tania Garfias-Veitl, Monika Diek, Mahir Karakas, Ralf Birkemeyer, Gerasimos Fillippatos, Piotr Ponikowski, Michael Böhm, Tim Friede, Stefan D. Anker

  2023-12-27

  https://doi.org/10.4081/cardio.2023.15

  2517

  pdf: 546

  HTML: 30

• Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial

  Wolfram Doehner, Tim Friede, Frank Edelmann, Ulf Landmesser, Sebastian Winkler, Burkert Pieske, Fabian Knebel, Sebastian Kelle, Diethelm Tschöpe, Antje Meyer, Nadja Jauert, Marius Placzek, Jeanette Schulz-Menger, Stephan von Haehling, Stefan D. Anker

  2025-12-31

  https://doi.org/10.4081/cardio.2025.89

  8

  PDF: 4

  Appendix: 0
• 

  Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients

  Javed Butler, Sanjiv J. Shah, Melissa Magwire, Carlos Campos, Muhammad Shariq Usman, Anthony Hoovler, Anup Sabharwal, Barry A. Borlaug

  2024-06-28

  https://doi.org/10.4081/cardio.2024.38

  1886

  PDF: 516

  SUPPLEMENTARY MATERIAL: 299

  GRAPHICAL ABSTRACT: 265

  HTML: 26
• 

  Using multiple primary endpoints in clinical trials with a focus on heart failure

  Stefan D. Anker, Javed Butler, Khawaja M. Talha, Tim Friede

  2024-06-28

  https://doi.org/10.4081/cardio.2024.33

  5505

  PDF: 724

  HTML: 189

• Dyslipidemia and stroke-related mortality in the United States: a nationwide analysis for 2010-2020

  Muhammad Muneeb Ur Rehman, Iliyan Mithani, Muhammad Sameer Arshad, Syed Raza Shah, Wolfram Doehner, Anandita Kulkarni

  2025-12-31

  https://doi.org/10.4081/cardio.2025.90

  1

  PDF: 1

  Supplementary: 0
• 

  Relaxin-2 for heart failure with preserved ejection fraction: a comment on the termination of a phase-II trial investigating the relaxin-2 analogue, LY3540378

  Thomas Bernd Dschietzig, Guy Salama

  2024-12-30

  https://doi.org/10.4081/cardio.2024.56

  3946

  PDF: 912

  HTML: 79